Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

Key Moments

  • PepsiCo Inc (PEP) trades pre-market at $130.78, sitting just above its $127.98 52-week low as of September 24, 2026 at 5:36 AM EDT.
  • Citi reiterated a Buy rating with a $142 price target on September 24, 2026, even as Q3 EPS estimates fell 5.24% over the past 90 days.
  • Q3 results are slated for October 8, 2026 pre-market, with consensus looking for $2.30 EPS and $25.00B in revenue.

Valuation Under Pressure Near 52-Week Lows

PepsiCo Inc (PEP) has been sliding toward the bottom of its recent trading range and is not yet presenting what some investors might call a straightforward dip-buying opportunity. The stock is changing hands at $130.78 in pre-market trading as of September 24, 2026 at 5:36 AM EDT, placing it only slightly above its 52-week low of $127.98.

Against this backdrop, Citi has reaffirmed a constructive stance. In an analyst update dated September 24, Citi maintained its Buy rating on PepsiCo and kept a $142 price target in place. The update was published on September 24, 2026.

Citi Flags Earnings Risk Ahead of Q3 Release

The near-term focal point for investors is PepsiCo’s upcoming quarterly report. The company is scheduled to release Q3 results on October 8, 2026, before the market opens. Current consensus forecasts call for earnings per share of $2.30 and revenue of $25.00B.

However, expectations have been drifting lower. Over the past 90 days, consensus EPS estimates have been reduced by 5.24%, reflecting growing caution around the quarter.

The most recent quarter sent mixed signals. PepsiCo delivered revenue ahead of expectations, but earnings per share came in slightly below forecasts. Following that report, the stock declined 3.60%, as investors focused less on the revenue beat and more on margins and the overall quality of operating performance.

Additional concerns have emerged from other research houses. BNP Paribas Exane pointed to demand softness in North America and lowered its price target to $161. TD Cowen has also underscored the risk from commodity costs. These views were published on September 23, 2026.

Valuation Support Versus Weak Price Momentum

From a fundamental perspective, valuation and income characteristics offer some support. PepsiCo’s trailing price-to-earnings ratio stands at 17.0x as of June 30, 2026. The forward P/E is 15.2x as of December 31, 2026, and the stock carries a dividend yield of 4.5% as of September 24, 2026.

Technical signals, however, are unfavorable. On both daily and weekly time frames, the stock is flashing Strong Sell indications. The relative strength index (RSI) is around 30.3 on the daily chart and 33.8 on the weekly chart. While those readings fall into oversold territory, the current setup suggests that oversold levels can persist without immediately triggering a reversal.

Key Technical Levels

Traders and investors are watching a set of nearby support and resistance levels as the stock approaches earnings.

Time FrameLevel TypePrice
DailySupport 1$129.36
DailySupport 2$128.79
WeeklySupport 1$126.60
WeeklySupport 2$123.45
WeeklyResistance$135.85

Risk-Reward Profile and Watch Points

The current setup presents an asymmetrical profile that is not straightforward. On one side, valuation metrics and the 4.5% dividend yield provide a cushion. On the other, questions remain around demand trends, commodity-cost exposure, and the company’s ability to deliver on Q3 expectations.

A more structured approach suggested by the recent analysis is to monitor whether PepsiCo Inc (PEP) can maintain support in the $127.98–$129.36 area and whether management reiterates or safeguards its full-year outlook. A decisive move below that price band would imply that the market is pricing in more than a mildly disappointing quarter.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • Oil weekly recap, March 17 – March 21Oil weekly recap, March 17 – March 21 West Texas Intermediate crude rose on Friday and ended two straight weeks of losses as renewed tension between Russia and the West raised oils risk premium. Ample US crude supplies and a strong dollar however checked gains. A more positive US […]
  • Tesla Tokenized Futures Hover at Key Pivot SupportTesla Tokenized Futures Hover at Key Pivot Support Key Moments The Tesla tokenized stock contract on Binance Futures traded at $383.10 with a 24-hour gain of 0.06% and a tight range between $381.92 and $386.06. All major moving averages, including the SMA 7, 20, 50, 200 and EMA […]
  • Natural gas trading outlook: futures climb ahead of the EIA reportNatural gas trading outlook: futures climb ahead of the EIA report Natural gas futures were higher during early trade in Europe today, ahead of the US weekly inventories levels report. Analysts suggest another sizable gain for nat gas stocks, while weather patterns project more moderate weather for the US in […]
  • Commodities trading outlook: crude oil futures slide, natural gas climbsCommodities trading outlook: crude oil futures slide, natural gas climbs WTI and Brent futures slid under pressure from disappointing Chinese figures today, while investors also kept an eye of developments over Ukraine. Meanwhile, natural gas futures climbed to reverse some of last weeks slump.On the New York […]
  • AWS Faces Scrutiny After AI-Linked December OutagesAWS Faces Scrutiny After AI-Linked December Outages Key Moments Amazon Web Services encountered at least two December outages tied to its own AI tools, according to a Financial Times report. A 13-hour mid-December disruption reportedly followed changes executed by AWS’s Kiro AI […]
  • Scholar Rock shares surge 26% as rival Biohaven misses SMA study goalScholar Rock shares surge 26% as rival Biohaven misses SMA study goal The shares of Scholar Rock Holding Corp (NASDAQ: SRRK) soared 26.07% on Monday, after an experimental, muscle-preserving drug by competitor Biohaven missed its goal in a Phase 3 study of people suffering from spinal muscular atrophy […]